jcm-logo

Journal Browser

Journal Browser

Age-Related Macular Degeneration: Challenges and Opportunities

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".

Deadline for manuscript submissions: 20 February 2026 | Viewed by 656

Special Issue Editor


E-Mail Website
Guest Editor
Department of Ophthalmology and Visual Sciences, University of Alabama at Birmingham, Birmingham, AL, USA
Interests: structural biomarkers; clinical trial endpoints; structure-function research; artificial intelligence; OCT-angiography; visual function

Special Issue Information

Dear Colleagues,

Age-related macular degeneration (AMD) is a complex, multifactorial disease characterized by progressive photoreceptor and retinal pigment epithelium degeneration, predominantly affecting individuals over 60 years of age. Genetic and lifestyle factors interact to contribute to its etiology. While recent advancements have yielded biologic therapies inhibiting vascular endothelial growth factor for neovascular AMD and complement activation for geographic atrophy, these treatments are limited by cost, injection-related risks, and suboptimal efficacy. Consequently, there is a need for novel, targeted therapies with improved endpoints that demonstrate both structural and functional benefits. A significant barrier to AMD drug discovery and research is the absence of preclinical models accurately recapitulating the phenotypes and progression of dry AMD.

This Special Issue, entitled “Age-Related Macular Degeneration: Challenges and Opportunities”, aims to collate submissions that advance our current understanding of existing gaps in the literature and identify new directions in clinical AMD research. Papers related to the topics mentioned in the Keywords are welcome to be submitted.

Topics of interest include the following:

  • Epidemiology and genetics of AMD;
  • Biomarkers for AMD detection and stratification;
  • Structural and functional endpoints;
  • Use of artificial intelligence in AMD research;
  • Role of complement system in AMD pathogenesis;
  • Role of oxidative stress in AMD;
  • Cell culture and preclinical animal models of AMD;
  • Novel drug delivery mechanisms for AMD.

Dr. Deepayan Kar
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • age-related macular degeneration
  • imaging biomarkers
  • visual function testing
  • optical coherence tomography
  • anti-VEGF
  • complement
  • artificial intelligence

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 2907 KB  
Article
The Effects of the COVID-19 Pandemic on the Follow-Up of Patients with Age-Related Macular Degeneration in a Tertiary Hospital in London, the UK
by Inés López-Cuenca, Lorenzo Fabozzi, Saad Younis, Ahmad Ali, José M. Ramírez, Maria Francesca Cordeiro and Rosa de Hoz
J. Clin. Med. 2025, 14(18), 6497; https://doi.org/10.3390/jcm14186497 - 15 Sep 2025
Viewed by 539
Abstract
Background/Objectives: Adherence to medical appointments is crucial for managing age-related macular degeneration (AMD). The COVID-19 pandemic disrupted healthcare services, potentially affecting disease control. This study aimed to assess the impact of the pandemic on appointment adherence and disease progression in AMD patients at [...] Read more.
Background/Objectives: Adherence to medical appointments is crucial for managing age-related macular degeneration (AMD). The COVID-19 pandemic disrupted healthcare services, potentially affecting disease control. This study aimed to assess the impact of the pandemic on appointment adherence and disease progression in AMD patients at the Western Eye Hospital in London. Methods: Patients were divided into two groups: those who attended appointments on time and those who experienced delays (n = 100 per group). We compared disease progression using demographic data, best-corrected visual acuity (BCVA), and macular thickness measured by OCT, extracted from medical records. Results: In patients without delays, BCVA remained stable pre- and post-COVID-19, although significant changes in macular thickness were observed in the central (C0), superior (S1, S2), nasal (N1), and inferior (I1, I2) macular sectors. In contrast, patients with delayed appointments showed a significant increase in N1 macular thickness from 324.00 (304.00–358.00) pre-COVID-19 to 337.50 (305.50–375.50) post-COVID-19 (p = 0.030). Post-COVID-19, patients without delays had significantly better BCVA and thinner N1 macular thickness than those with delays. A positive correlation was found between the length of appointment delays and increased macular thickness in S1 and I2 sectors. Conclusions: Timely follow-up is essential in AMD management. Appointment delays during the COVID-19 pandemic were associated with increased macular thickness and worse visual outcomes, highlighting the importance of maintaining continuity of care even during healthcare disruptions. Full article
(This article belongs to the Special Issue Age-Related Macular Degeneration: Challenges and Opportunities)
Show Figures

Figure 1

Back to TopTop